EcoDrugPlus

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSPREG00000006269
Gene Symbol: LOC103458160
3 Cross references
193 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSPREG00000019634
Gene Symbol: FLT1
3 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSPREG00000005213
Gene Symbol: FLT4
3 Cross references
193 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSPREG00000019604
Gene Symbol: FOLH1B
3 Cross references
339 Possible Orthologues:

Folate Receptor Beta

Ensembl ID : ENSPREG00000019427
Gene Symbol: FOLR2
3 Cross references
436 Possible Orthologues:

Follicle-Stimulating Hormone Receptor-Like

Ensembl ID : ENSPREG00000005324
Gene Symbol: LOC103481549
3 Cross references
200 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSPREG00000006684
Gene Symbol: LOC103477767
2 Cross references
338 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSPREG00000012658
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSPREG00000018054
Gene Symbol: LOC103458310
3 Cross references
220 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2-Like

Ensembl ID : ENSPREG00000003851
Gene Symbol: LOC103471038
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSPREG00000005068
Gene Symbol: GABRA1
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSPREG00000017800
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).